GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Based on the review, the researchers promote the integration of GLP-1 receptor agonists as a primary treatment for obesity in ...

Glucagon-like peptide-1 receptor agonists are FDA-approved medications that mimic the action of a naturally occurring hormone ...

They work by mimicking the action of a hormone called glucagon-like peptide 1 (hence GLP-1), stimulating the body to produce more insulin and decreasing blood sugar spikes by slowing digestion.

The drugmaker has already taken legal action against some businesses selling compounded semaglutide in a way that does not comply with the FDA's regulations. The price of GLP-1 drugs has attracted ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...